Immunocytochemical demonstration of S-phase cells by anti-bromodeoxyuridine monoclonal antibody in human brain tumor tissues.
Five patients with various brain tumors received bromodeoxyuridine (BrdU), 150-200 mg/m2 i.v., at the time of craniotomy. Biopsied materials were fixed in 70% ethanol, sectioned, denatured with hydrochloric acid, and reacted with monoclonal antibodies against BrdU. Immunofluorescence and immunocytochemical methods were used to visualize BrdU-labeled nuclei. Our results showed that both methods demonstrated BrdU-labeled nuclei satisfactorily in tissue sections. Thus, BrdU can be used to measure the proliferative potential of human tumors in situ.
Nagashima
T
T
DeArmond
S J
SJ
Murovic
J
J
Hoshino
T
T
D000368:Aged; D000911:Antibodies, Monoclonal; D001254:Astrocytoma / Q000473:pathology; D001932:Brain Neoplasms / Q000473:pathology*; D001973:Bromodeoxyuridine / Q000276:immunology*; D002675:Child, Preschool; D005260:Female; D005909:Glioblastoma / Q000473:pathology; D005910:Glioma / Q000473:pathology; D006651:Histocytochemistry; D006801:Humans; D007120:Immunochemistry; D007399:Interphase; D008297:Male; D008579:Meningioma / Q000473:pathology; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D001973:Bromodeoxyuridine